In the article beginning on page 1102 in the 3 March 2016 issue, there are errors in some of the data related to patients’ ages. The median age of patients in the lenalidomide-dexamethasone (Rd) group should be 73 years, not 74 years (fifth sentence of “Results,” pages 1103-1104, and Table 1, page 1105).
In Table 1, the numbers of patients who are ages >75 years should be 80 (37%), not 86 (39%), in the melphalan-prednisone-lenalidomide (MPR) group; 73 (33%), not 80 (36%), in the cyclophosphamide-prednisone-lenalidomide (CPR) group; and 77 (35%), not 83 (37%), in the Rd group. The corrected Table 1 is shown below.
The authors confirm that these modifications do not affect the results of the analyses. The errors have been corrected in the online version, which now differs from the print version.
